Correlation Between Nuvectis Pharma and Biomea Fusion

Can any of the company-specific risk be diversified away by investing in both Nuvectis Pharma and Biomea Fusion at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Nuvectis Pharma and Biomea Fusion into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Nuvectis Pharma and Biomea Fusion, you can compare the effects of market volatilities on Nuvectis Pharma and Biomea Fusion and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Nuvectis Pharma with a short position of Biomea Fusion. Check out your portfolio center. Please also check ongoing floating volatility patterns of Nuvectis Pharma and Biomea Fusion.

Diversification Opportunities for Nuvectis Pharma and Biomea Fusion

-0.62

Correlation Coefficient

Nuvectis Pharma  Biomea Fusion

Excellent diversification

The 3 months correlation between Nuvectis and Biomea is -0.62. Overlapping area represents the amount of risk that can be diversified away by holding Nuvectis Pharma and Biomea Fusion in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Biomea Fusion and Nuvectis Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Nuvectis Pharma are associated (or correlated) with Biomea Fusion. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Biomea Fusion has no effect on the direction of Nuvectis Pharma i.e., Nuvectis Pharma and Biomea Fusion go up and down completely randomly.

Pair Corralation between Nuvectis Pharma and Biomea Fusion

Given the investment horizon of 90 days Nuvectis Pharma is expected to generate 0.89 times more return on investment than Biomea Fusion. However, Nuvectis Pharma is 1.12 times less risky than Biomea Fusion. It trades about 0.12 of its potential returns per unit of risk. Biomea Fusion is currently generating about -0.26 per unit of risk. If you would invest  504.00  in Nuvectis Pharma on November 29, 2024 and sell it today you would earn a total of  167.00  from holding Nuvectis Pharma or generate 33.13% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Nuvectis Pharma  vs.  Biomea Fusion

Nuvectis Pharma

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Nuvectis Pharma are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively conflicting fundamental indicators, Nuvectis Pharma unveiled solid returns over the last few months and may actually be approaching a breakup point.

Biomea Fusion

Risk-Adjusted Performance

Very Weak

Over the last 90 days Biomea Fusion has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's technical and fundamental indicators remain somewhat strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Nuvectis Pharma and Biomea Fusion

The main advantage of trading using opposite Nuvectis Pharma and Biomea Fusion positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Nuvectis Pharma position performs unexpectedly, Biomea Fusion can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biomea Fusion will offset losses from the drop in Biomea Fusion's long position.

The idea behind Nuvectis Pharma and Biomea Fusion pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.